Clinically Apparent Atrial Fibrillation Increases Stroke Risk; Does Subclinical AFib Do the Same?

Published Online: Tuesday, January 14, 2014
Follow Pharmacy_Times:
Stuart J. Connelly, MD, one of the principal authors of “Subclinical Atrial Fibrillation and the Risk of Stroke,” published in the New England Journal of Medicine, talks about the study.  

To listen to the podcast, click here.
Related Articles
The JNC 8 guidelines are based on 27 large clinical trials that are often discussed in isolation, but have never been aggregated into a single source until now.
A new cardiovascular risk estimator can accurately predict heart disease and stroke risk for anyone in the world aged 40 years or older.
While the FDA only recommends daily aspirin for patients who have experienced major cardiovascular events, about half of older adults in the United States take aspirin regularly.
Pharmacist-driven drug management programs best ensure atrial fibrillation patients adhere to the warfarin alternative, dabigatran (Pradaxa).
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$